

DAFTAR PUSTAKA

- [1] International Agency for Research on Cancer dan World Health Organization (OMS), “*GLOBOCAN 2018: Latest global cancer data. Press release No 263.*,” no. September, pp. 13–15, 2018.’
- [2] S. Gondhowiardjo, G. Prajogi, dan S. Sekarutami, “History and growth of radiation oncology in Indonesia,” *Biomed. Imaging Interv. J.*, vol. 4, no. 3, 2008.
- [3] National Cancer Institute, “Support for People With Cancer - Radiation Therapy and You,” *U.S. Dep. Heal. Hum. Serv. - Natl. Institutes Heal.*, pp. 1–60, 2012.
- [4] Emiliano Spezi dan Geraint Lewis, “An overview of Monte Carlo treatment planning for radiotherapy,” *Radiat. Prot. Dosimetry*, vol. 131, no. 1, pp. 123–129, 2008.
- [5] Niels Bassler, David C. Hansen, Armin Lühr, B. Thomsen, J. B. Petersen, dan Nikolay Sobolevsky, “SHIELD-HIT12A - A Monte Carlo particle transport program for ion therapy research,” *J. Phys. Conf. Ser.*, vol. 489, no. 1, 2014.
- [6] Igor J. Barani dan David A. Larson, “Radiation Therapy of Glioblastoma,” *Cancer Treat. Res.*, vol. 163, 2015.
- [7] Dwi Berlianti Siwi. *Analisis Dosis di Organ Kritis Pada Terapi Glioblastoma Dengan Boron Neutron Capture Therapy Menggunakan Metode Simulasi MCNP5*. Skripsi, Jurusan Teknik Fisika, Fakultas Teknik, Universitas Gadjah Mada, Yogyakarta, 2013.
- [8] Katarzyna Tyminska, Karol Jezierski, dan Jakub Osko, “A virtual model of the patient’s head for BNCT,” *Polish J. Med. Phys. Eng.*, vol. 15, no. 3, pp. 113–119, 2009.
- [9] J. M. Mosthaf, A. Peters, T. Haberer, K. Höppner, dan S. Hanke, “Status Update For The Hit Accelerator Control System,” pp. 1409–1411.
- [10] Emami B., “Tolerance of Normal Tissue to Therapeutic Radiation,” vol. 1, no. 1, pp. 35–48, 2013.
- [11] Fen Zhao, Minghuan Li, Li Kong, Gouli Zhang, dan Jinming Yu, “Delineation of radiation therapy target volumes for patients with postoperative glioblastoma: A review,” *Onco. Targets. Ther.*, vol. 9, pp. 3197–3204, 2016.
- [12] Joe Y. Chang dan James D. Cox, “Proton Therapy,” *Lung Cancer Fourth*

Ed., vol. 9781118468, no. August, pp. 338–352, 2014.

- [13] PTCOG, “SHIELDING DESIGN DAN RADIATION SAFETY OF CHARGED PARTICLE THERAPY FACILITIES - Report 1,” *PTCOG Publ.*, vol. 1, no. January, p. 396, 2010.
- [14] International Commission on Radiation Units, *ICRU Report 59*, Maryland, 1998.
- [15] International Commission on Radiation Protection, *ICRP Publication 103*, Maryland, 2007.
- [16] International Commission on Radiation Units, *ICRU Report 49*, Maryland, 1993.
- [17] International Atomic Energy Agency, “Cyclotron Produced Radionuclides: Principles dan Practice,” *Tech. Rep. Ser.*, vol. 465, no. 465, 2008.
- [18] Rolf F. Barth, Jeffrey A. Coderre, M. Graca H. Vicente, dan Thomas E. Blue, “Boron neutron capture therapy of brain tumors - Current status dan future prospects,” *J. Neurooncol.*, vol. 33, no. 1–2, pp. 3–7, 1997.
- [19] Shin-Ichi Miyatake, Shinji Kawabata, Ryo Hiramatsu, Toshihiko Kuroiwa, Minorou Suzuki, Natsuko Kondo, dan Koji Ono, “Boron neutron capture therapy for malignant brain tumors,” *KURRI Prog. Rep.*, p. 140, 2004.
- [20] INTERNATIONAL ATOMIC ENERGY AGENCY, “Current status of neutron capture therapy,” *International Atomic Energy Agency, 2001*, no. May, pp. 75–77, 2001.
- [21] Metropolis N, “The Beginning of the Monte Carlo Method,” *J. Clin. Microbiol.*, vol. 50, no. 1, pp. 81–85, 2012.
- [22] Dirk P. Kroese, Tim Brereton, Thomas Taimre, dan Zdravko I. Botev, “Why the Monte Carlo method is so important today,” *Wiley Interdiscip. Rev. Comput. Stat.*, vol. 6, no. 6, pp. 386–392, 2014.
- [23] Nikolay Sobolevsky, “Multipurpose Hadron Transport Code.” Diakses dari <http://www.inr.ru/shield/introd-eng.html>, 29 Juni 2019.
- [24] Fonnert E. Bleeker, Remco J. Molenaar, dan Sieger Leenstra, “Recent advances in the molecular understanding of glioblastoma,” *J. Neurooncol.*, vol. 108, no. 1, pp. 11–27, 2012.
- [25] David N. Louis, Arie Perry, Guido Reifenberger, Andreas von Deining, Dominique Figarella-Branger, Webster K. Cavance, Hiroko Ohgaki, Otmar D. Wlester, Paul Kleiheus, Dacid W. Ellison “The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary,” *Acta Neuropathol.*, vol. 131, no. 6, pp. 803–20, 2016.
- [26] O. Gallego, “Nonsurgical treatment of recurrent glioblastoma,” *Curr. Oncol.*, vol. 22, no. 4, pp. e273–e281, 2015.

- [27] Shelley McGuire, “World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015,” *Adv. Nutr.*, vol. 7, no. 2, pp. 418–419, 2016.
- [28] Richard M. Young, Aria Jamshidi, Ggregory Davis, dan Jonathan H. Sherman, “Current trends in the surgical management dan treatment of adult glioblastoma,” *Ann Transl Med*, vol. 3, no. 9, p. 121, 2015.
- [29] H. Christoper Lawson, Prakash Sampath, Eileen Bohan, Michael C. Park, Namath Hussain, Alessandro Olivi, Jon Weingart, Lawrence Kleinberg, dan Henry Brem, “Interstitial chemotherapy for malignant gliomas: The Johns Hopkins experience,” *J. Neurooncol.*, vol. 83, no. 1, pp. 61–70, 2007.
- [30] International Commision on Radiation Units, *ICRU report 44*. Maryland, 1998.
- [31] Wira Bahari Nurdin, Aji Purnomo, dan Syamsir Dewang, “Source to Skin Distance (SSD) Characteristics from Varian CX Linear Accelerator,” *J. Phys. Conf. Ser.*, vol. 979, no. 1, 2018.